|35.66|| +1.26 / +3.66%|
Radius Health, Inc. a biopharmaceutical company, which engages in the discovery and development of therapeutics for the treatment of osteoporosis and other women's health conditions. Its BA058 Injection product is a daily subcutaneous injection of novel synthetic peptide analog of human parathyroid hormone-related protein. The company also develops BA058 Microneedle Patch; RAD1901, a selective estrogen receptor modulator for the treatment of vasomotor symptoms in women entering menopause; and RAD140, a selective androgen receptor modulator. Its initial business was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt and John T. Potts on October 3, 2003. Radius Health was founded on February 4, 2008 and is headquartered in Cambridge, MA.
|Robert E. Ward||President, Chief Executive Officer & Director|
|Brian Nicholas Harvey||CFO, Secretary, Treasurer & Senior Vice President|
|Gary Hattersley||Chief Scientific Officer & Senior Vice President|
|Lorraine A. Fitzpatrick||Chief Medical Officer|
|Dinesh Purandare||Senior Vice President & Head-Global Oncology|